| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/12/2002 | WO2002070700A1 Polynucleotide useful for modulating cancer cell proliferation |
| 09/12/2002 | WO2002070698A2 Modified ciliary neurotrophic factor (cntf) with reduced immunogenicity |
| 09/12/2002 | WO2002070697A1 Mammalian nuclear receptor l67 and methods of use |
| 09/12/2002 | WO2002070696A2 Cd109 nucleic acid molecules polypeptides and methods of use |
| 09/12/2002 | WO2002070694A2 Methods and compositions for modifying a receptor tyrosine kinase/protein tyrosine kinase signal to an apoptotic signal in a cell |
| 09/12/2002 | WO2002070693A2 Novel abca6 transporter and uses thereof |
| 09/12/2002 | WO2002070692A2 Abca9 transporter and uses thereof |
| 09/12/2002 | WO2002070691A2 Abcg4 transporter and uses thereof |
| 09/12/2002 | WO2002070690A2 Abca5 transporter and uses thereof |
| 09/12/2002 | WO2002070681A1 Protein c variants |
| 09/12/2002 | WO2002070680A1 Method of identifying inhibitors of cdc25 |
| 09/12/2002 | WO2002070679A2 Peptide fragments, derived from human telomerase reverse transcriptase |
| 09/12/2002 | WO2002070676A2 Use of protein histidine phosphatase |
| 09/12/2002 | WO2002070669A2 Secreted proteins |
| 09/12/2002 | WO2002070666A2 Compositions and methods for regulating autolytic processes in bacteria |
| 09/12/2002 | WO2002070665A2 Recombinant hybrid allergen constructs with reduced allergenicity that retain immunogenicity of the natural allergen |
| 09/12/2002 | WO2002070660A2 Proteins and nucleic acids encoding same |
| 09/12/2002 | WO2002070657A2 93870, a human g-protein coupled receptor and uses therefor |
| 09/12/2002 | WO2002070655A2 Mouse cytokine receptor |
| 09/12/2002 | WO2002070652A2 Novel molecules of the card-related protein family and uses thereof |
| 09/12/2002 | WO2002070647A2 Denaturat stable and/or protease resistant, chaperone-like oligomeric proteins, polynucleotides encoding same and their uses |
| 09/12/2002 | WO2002070646A2 Matrix stabilized enzyme crystals and methods of use |
| 09/12/2002 | WO2002070594A2 A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge |
| 09/12/2002 | WO2002070565A2 High-affinity antagonists of elr-cxc chemokines |
| 09/12/2002 | WO2002070563A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070562A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070561A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070560A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070559A2 Nuclear hormone receptor ligand binding domains |
| 09/12/2002 | WO2002070558A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070557A2 Nuclear hormone receptor ligand binding domain |
| 09/12/2002 | WO2002070556A1 POLYPEPTIDE OF A P53 PROTEIN-SPECIFIC MURINE Α/β T-CELL RECEPTOR, NUCLEIC ACIDS CODING THEREFOR AND USE THEREOF |
| 09/12/2002 | WO2002070555A2 Method of modulating the proliferation of medullary thyroid carcinoma cells |
| 09/12/2002 | WO2002070553A1 Tumour peptide antigen produced from human mdm2 proto-oncogene |
| 09/12/2002 | WO2002070552A2 POLYPEPTIDE FROM A HDM2 PROTEIN SPECIFIC MURINE Α/β T-CELL RECEPTORS, NUCLEIC ACIDS CODING FOR THE ABOVE AND USE THEREOF |
| 09/12/2002 | WO2002070551A2 Neuritogenic compound and uses thereof |
| 09/12/2002 | WO2002070549A2 Chimeric polypeptides of serum albumin and uses related thereto |
| 09/12/2002 | WO2002070548A2 Modified human granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity |
| 09/12/2002 | WO2002070547A1 Template-fixed peptidomimetics with antimicrobial activity |
| 09/12/2002 | WO2002070546A2 Modified derivatives of cck-8 |
| 09/12/2002 | WO2002070545A2 Siderophore analogues as tetra- or hexadentate iron chelators on the basis of amino acids or peptides, method for producing them and the use thereof |
| 09/12/2002 | WO2002070538A2 Narc8 programmed cell-death-associated molecules and uses thereof |
| 09/12/2002 | WO2002070536A1 Antisense modulation of recql2 expression |
| 09/12/2002 | WO2002070535A1 Antisense modulation of recql5 expression |
| 09/12/2002 | WO2002070511A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 09/12/2002 | WO2002070493A1 Bisaryl derivatives having fsh receptor modulatory activity |
| 09/12/2002 | WO2002070023A2 Compositions comprising bone marrow cells together with demineralized and/or mineralized bone matrix and uses thereof in the induction of bone and cartilage formation |
| 09/12/2002 | WO2002070019A1 Nucleic acid constructs, cells transformed therewith and methods utilizing same for inducing liver regeneration and alleviation of portal hypertension |
| 09/12/2002 | WO2002070011A2 Treatment of ppar mediated diseases |
| 09/12/2002 | WO2002070010A1 Graft rejection inhibitors |
| 09/12/2002 | WO2002070009A1 Preventives/remedies for thickened scar, keloid or chronic arthritic diseases |
| 09/12/2002 | WO2002070008A1 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| 09/12/2002 | WO2002070006A2 Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses |
| 09/12/2002 | WO2002070005A1 Compositions of multimeric profilin for diagnosis and treatment of allergies |
| 09/12/2002 | WO2002070002A2 Methods for regulation of immune responses to conditions involving mediator-induced pathology |
| 09/12/2002 | WO2002070001A2 Use of lp82 to treat hematopoietic disorders |
| 09/12/2002 | WO2002070000A1 Recombinant gelatin-like proteins for use as plasma expanders |
| 09/12/2002 | WO2002069999A1 Stable aqueous solutions of granulocyte macrophage colony-stimulating factor |
| 09/12/2002 | WO2002069998A1 Regulating vegf expression by a protein of the tis11 family |
| 09/12/2002 | WO2002069997A1 Modified protamine with reduced immunogenicity |
| 09/12/2002 | WO2002069996A1 Induced metaplastic mucous cell apoptosis |
| 09/12/2002 | WO2002069995A2 Use of trail and antiprogestins for treating cancer |
| 09/12/2002 | WO2002069994A2 Combined use of derivatives of glp-1 analogs and ppar ligands |
| 09/12/2002 | WO2002069988A2 Compositions comprising bone marrow cells together with demineralized and/or mineralized bone matrix and their use in bone marrow transplantation |
| 09/12/2002 | WO2002069964A1 Enteral formulation |
| 09/12/2002 | WO2002069955A1 Method and formula for anti-tumor and anti-matastatic effect |
| 09/12/2002 | WO2002069947A2 Antisense oligonucleotides and trichostatin analogue histone deacetylase-4 inhibitors against cancer |
| 09/12/2002 | WO2002069937A1 Compounds and compositions for delivering active agents |
| 09/12/2002 | WO2002069930A1 Compositions and methods for enhancing drug delivery across and into epithelial tissues |
| 09/12/2002 | WO2002069913A1 Skin-improving composition set |
| 09/12/2002 | WO2002069908A2 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| 09/12/2002 | WO2002069907A2 Anti-neovasculature preparations for cancer |
| 09/12/2002 | WO2002069906A2 Compounds and methods for the treatment of urogenital disorders |
| 09/12/2002 | WO2002069905A2 Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders |
| 09/12/2002 | WO2002069902A2 Cyclosporins for the treatment of respiratory diseases |
| 09/12/2002 | WO2002069896A2 Connexin enhances chemotherapy-induced apoptosis in human cancer cells inhibiting tumor cell proliferation |
| 09/12/2002 | WO2002069886A2 Modified proteins, designer toxins, and methods of making thereof |
| 09/12/2002 | WO2002069885A2 Anti-invasive and anti-angiogenic compositions and methods for treating brain tumors and other diseases |
| 09/12/2002 | WO2002069884A2 A sunburn treatment and sunburn prevention method |
| 09/12/2002 | WO2002069876A1 Method for treatment of neurodegenerations |
| 09/12/2002 | WO2002069689A2 Gssp4 polynucleotides and polypeptides and uses thereof |
| 09/12/2002 | WO2002063010A9 Method of producing recombinant antibodies against tumors |
| 09/12/2002 | WO2002057409A3 Antisense modulation of src-2 expression |
| 09/12/2002 | WO2002053175A3 Use of botulinum toxin for treatment of articular pathologies |
| 09/12/2002 | WO2002052274A3 Screening method based on tsap6 binding partners |
| 09/12/2002 | WO2002051986A3 Educated nk t cells and their uses in the treatment of immune-related disorders |
| 09/12/2002 | WO2002050111A3 Isolated laminin 10 |
| 09/12/2002 | WO2002050103A3 Tumour-related antigens |
| 09/12/2002 | WO2002050100A3 Diaminodicarboxylic acid: peptide-based gemini surfactant compounds used for drug delivery |
| 09/12/2002 | WO2002049576A3 Fab i and inhibition of apicomplexan parasites |
| 09/12/2002 | WO2002044358A3 Methods and compositions for diagnosis and treatment of cancer using arginine m ethyltransferase 3 |
| 09/12/2002 | WO2002044113A3 Use of(-) (3-halomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
| 09/12/2002 | WO2002040500A3 Method of prognosis and diagnosis of congestive heart failure |
| 09/12/2002 | WO2002030969A3 Regulation of human carboxylesterase-like enzyme |
| 09/12/2002 | WO2002030442A3 Use of [d-leu2]-deltrophin for treating cytokine mediated hgepatic injury |
| 09/12/2002 | WO2002028997A3 Methods of isolating bipotent hepatic progenitor cells |
| 09/12/2002 | WO2002022680A3 Site-specific, antibody-mediated activation of proapoptotic cytokine: amaice (antibody-mediated apoptosis inducing cytokine) |
| 09/12/2002 | WO2002016410A3 Peptide selection method |
| 09/12/2002 | WO2002014369A3 Human kininogen d5 domain polypeptides and their use |
| 09/12/2002 | WO2002012476A3 Compositions and methods for the therapy and diagnosis of pancreatic cancer |